Evidence-informed practice: Diagnostic questions in urinary tract infections in the fielderly

Western Journal of Emergency Medicine

Volumn 20, Issue 4, 2019, Pages 573-577

  Pescatore, Richard ^d   Niforatos, Joshua D ^a   Rezaie, Salim ^b   Swaminathan, Anand ^c  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b Greater San Antonio Area Hospital Council   (United States)

^c ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^d Crozer Keystone Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INTERLEUKIN 6; PROCALCITONIN; BIOLOGICAL MARKER;

ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP; ASYMPTOMATIC BACTERIURIA; DISEASE ASSOCIATION; DISEASE SEVERITY; EMERGENCY WARD; EVIDENCE BASED MEDICINE; GERIATRIC DISORDER; GERIATRIC PATIENT; HEALTH CARE ACCESS; HUMAN; IMMUNE RESPONSE; POPULATION; PROTEIN DEGRADATION; PYURIA; REVIEW; RISK FACTOR; URINARY TRACT INFECTION; URINE CULTURE; AGED; ASYMPTOMATIC DISEASE; BACTERIURIA; BLOOD; HOSPITAL EMERGENCY SERVICE;

AGED; ASYMPTOMATIC DISEASES; BACTERIURIA; BIOMARKERS; EMERGENCY SERVICE, HOSPITAL; HUMANS; PROCALCITONIN; URINARY TRACT INFECTIONS;

EID: 85070393506     PISSN: 1936900X     EISSN: 19369018     Source Type: Journal    
DOI: 10.5811/westjem.2019.5.42096     Document Type: Review

References (42)

1. Pescatore R, Salzman M, Cassidy-Smith T, et al. The benefits and risks of asynchronous education. Acad Med. 2015;90(9):1183.
2. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71-2.
3. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.
4. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294(2):218-28.
5. Prasad V, Vandross A, Toomey C, et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc. 2013;88(8):790-8.
6. Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. JAMA. 2012;308(16):1676-84.
7. Fleming PS, Koletsi D, Ioannidis JP, et al. High quality of the evidence for medical and other health-related interventions was uncommon in Cochrane systematic reviews. J Clin Epidemiol. 2016;78:34-42.
8. Prasad V, Gall V, Cifu A. The frequency of medical reversal. Arch Intern Med. 2011;171(18):1675-6.
9. Freedman LR. Chronic pyelonephritis at autopsy. Ann Intern Med. 1967;66(4):697-710.
10. Kass EH. Pyelonephritis and bacteriuria. A major problem in preventive medicine. Ann Intern Med. 1962;56:46-53.
11. Nicolle LE. The paradigm shift to non-treatment of asymptomatic bacteriuria. Pathogens. 2016;5(2).
12. Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40(5):643-54.
13. Nicolle LE. Asymptomatic bacteriuria. Curr Opin Infect Dis. 2014;27(1):90-6.
14. Frazee BW, Enriquez K, Ng V, et al. Abnormal urinalysis results are common, regardless of specimen collection technique, in women without urinary tract infections. J Emerg Med. 2015;48(6):706-11.
15. Gupta K, Grigoryan L, Trautner B. Urinary tract infection. Ann Intern Med. 2017;167(7):ITC49-64.
16. Caterino JM, Kline DM, Leininger R, et al. Nonspecific symptoms lack diagnostic accuracy for infection in older patients in the emergency department. J Am Geriatr Soc. 2019;67(3):484-92.
17. Gandhi T, Flanders SA, Markovitz E, et al. Importance of urinary tract infection to antibiotic use among hospitalized patients. Infect Control Hosp Epidemiol. 2009;30(2):193-5.
18. Khawcharoenporn T, Vasoo S, Ward E, et al. Abnormal urinalysis finding triggered antibiotic prescription for asymptomatic bacteriuria in the ED. Am J Emerg Med. 2011;29(7):828-30.
19. Lee MJ, Kim M, Kim N-H, et al. Why is asymptomatic bacteriuria overtreated?: A tertiary care institutional survey of resident physicians. BMC Infect Dis. 2015;15:289.
20. Miller J. To treat or not to treat: managing bacteriuria in fielderly people. CMAJ. 2001;164(5):619-20.
21. Grönberg-Hernández J, Hernández JG, Sundén F, Connolly J, Svanborg C, Wullt B. Genetic control of the variable innate immune response to asymptomatic bacteriuria. PloS One. 2011;6(11):e28289.
22. Castell JV, Gómez-Lechón MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989;242(2):237-9.
23. Gruys E, Toussaint MJ, Niewold TA, et al. Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B. 2005;6(11):1045-56.
24. Linder A, Christensson B, Herwald H, et al. Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin Infect Dis. 2009;49(7):1044-50.
25. Kjölvmark C, Påhlman LI, Åkesson P, et al. Heparin-binding protein: a diagnostic biomarker of urinary tract infection in adults. Open Forum Infect Dis. 2014;1(1):ofu004.
26. Kjölvmark C, Tschernij E, Öberg J, et al. Distinguishing asymptomatic bacteriuria from urinary tract infection in the fielderly - the use of urine levels of heparin-binding protein and interleukin-6. Diagn Microbiol Infect Dis. 2016;85(2):243-8.
27. Quadir AF, Britton PN. Procalcitonin and C-reactive protein as biomarkers for neonatal bacterial infection. J Paediatr Child Health. 2018;54(6):695-9.
28. Memar MY, Varshochi M, Shokouhi B, et al. Procalcitonin: the marker of pediatric bacterial infection. Biomed Pharmacother. 2017;96:936-43.
29. Taggart K, Nielsen S. Procalcitonin as a biomarker of bacterial infection. S D Med. 2016;69(8):370-1.
30. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236-49.
31. van der Does Y, Limper M, Jie KE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre non-inferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect. 2018;24(12):1282-9.
32. Bremmer DN, Shively NR, Walsh TL. Procalcitonin-guided antibiotic use. N Engl J Med. 2018;379(20):1972.
33. Spellberg B, Gaffin N. Procalcitonin-guided antibiotic use. N Engl J Med. 2018;379(20):1972-3.
34. Pulia MS, Schulz LT, Fox BC. Procalcitonin-guided antibiotic use. N Engl J Med. 2018;379(20):1971-2.
35. Xu RY, Liu HW, Liu JL, et al. Procalcitonin and C-reactive protein in urinary tract infection diagnosis. BMC Urol. 2014;14:45.
36. Leroy S, Gervaix A. Procalcitonin: a key marker in children with urinary tract infection. Adv Urol. 2011;2011:397618.
37. Mantadakis E, Plessa E, Vouloumanou EK, et al. Serum procalcitonin for prediction of renal parenchymal involvement in children with urinary tract infections: a meta-analysis of prospective clinical studies. J Pediatr. 2009;155(6):875-81.e1.
38. Drozdov D, Schwarz S, Kutz A, et al. Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. BMC Med. 2015;13:104.
39. Shaikh N, Borrell JL, Evron J, et al. Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children. Cochrane Database Syst Rev. 2015;1:CD009185.
40. Jereb M, Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr. 2006;118(5-6):170-4.
41. Butbul-Aviel Y, Koren A, Halevy R, et al. Procalcitonin as a diagnostic aid in osteomyelitis and septic arthritis. Pediatr Emerg Care. 2005;21(12):828-32.
42. Levine AR, Tran M, Shepherd J, et al. Utility of initial procalcitonin values to predict urinary tract infection. Am J Emerg Med. 2018;36(11):1993-7.